ESALF News and Press, Eisai Co Ltd From 10/13/23

2023-10-13 13:05:06 ET A national policy that limited the use of a type of brain scan called positron emission tomography (PET) in testing for symptoms of Alzheimer's disease has been removed, the U.S. Centers for Medicare & Medicaid Services (CMS) said on Friday. The cause of the m...

Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023 TOKYO, Oct 11, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Societ...

Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc. TOKYO, Oct 4, 2023 - (JCN Newswire) - Eisai Co., Ltd. hereby announcesthat the Company has today decided to absorb and merge with KAN Research Institute, Inc., the Company's...

2023-10-03 13:53:21 ET More on ProMIS Neurosciences ProMIS Neurosciences scales 31% on $20.4M private placement ProMIS stock rockets 115% amid preclinical data for Alzheimer's drug Historical earnings data for ProMIS Neurosciences Financial information for Pr...

Eisai Launches New "Innovation" Page on Corporate Website TOKYO, Sept 28, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched a new "Innovation" page on its corporate website. The "Innovation" page is comprised of four sections: "Research & Development (...

Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance" TOKYO, Sept 28, 2023 - (JCN Newswire) - Tokio Marine & Nichido Fire Insurance Co., Ltd. and Eisai Co., Ltd. announced that they have co-developed "Dementia Care Support Insurance" to fin...

2023-09-25 06:55:38 ET More on Biogen, Eisai, etc. Eisai: Lumpy Rollout Of Leqembi, Economic Value Hard To Ascertain (Rating Downgrade) Biogen: Leqembi Could Boost Prospects Until Acquisition Comes Into Play Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And...

"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan TOKYO and CAMBRIDGE, Mass., Sept 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal ...

2023-09-23 16:00:00 ET More on GE Healthcare, Siemens, Biogen GE Healthcare: Revenue Growth, Margin Expansion And Attractive Valuation Siemens Healthineers: The Decline Makes The Upside Better Why Did GE HealthCare Excel Beyond The COVID-19 Crisis? Biogen: Le...

2023-09-22 16:01:40 ET Summary Eisai Co., Ltd. has experienced a sharp decline amid lumpy progress with its Alzheimer's disease drug, Leqembi. Q1 FY'23 numbers show modest growth in ESALF's pharmaceutical business, but revenue and operating income have decreased over time. ESA...